Literature DB >> 15177309

Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Maria Gabriella Scordo1, Achille P Caputi, Concetta D'Arrigo, Giuseppina Fava, Edoardo Spina.   

Abstract

The polymorphic cytochrome P450 isoenzymes (CYPs) 2C9, 2C19 and 2D6 metabolise many important drugs, as well as other xenobiotics. Their polymorphism gives rise to important interindividual and interethnic variability in the metabolism and disposition of several therapeutic agents and may cause differences in the clinical response to these drugs. In this study, we determined the genotype profile of a random Italian population in order to compare the CYP2C9, CYP2C19 and CYP2D6 allele frequencies among Italians with previous findings in other Caucasian populations. Frequencies for the major CYP2C9, CYP2C19 and CYP2D6 mutated alleles and genotypes have been evaluated in 360 unrelated healthy Italian volunteers (210 males and 150 females, aged 19-52 years). Genotyping has been carried out on peripheral leukocytes DNA by molecular biology techniques (PCR, RFLP, long-PCR). CYP2C9, CYP2C19 and CYP2D6 allele and genotype frequencies resulted in equilibrium with the Hardy-Weinberg equation. One hundred and fourteen subjects (31.7%) carried one and 23 subjects (6.4%) carried two CYP2C9 mutated alleles. Sixty-eight (18.9%) volunteers were found to be heterozygous and six (1.7%) homozygous for the CYP2C19*2, while no CYP2C19*3 was detected in the evaluated population. Volunteers could be divided into four CYP2D6 genotypes groups: 192 subjects (53.3%) with no mutated alleles (homozygous extensive metabolisers, EM), 126 (35.0%) with one mutated allele (heterozygous EM), 12 (3.4%) with two mutated alleles (poor metabolisers, PM) and 30 (8.3%) with extracopies of a functional gene (ultrarapid metabolisers, UM). Frequencies of both CYP2C9 and CYP2C19 allelic variants, as well as CYP2D6 detrimental alleles, in Italian subjects were similar to those of other Caucasian populations. Conversely, the prevalence of CYP2D6 gene duplication among Italians resulted very high, confirming the higher frequency of CYP2D6 UM in the Mediterranean area compared to Northern Europe. Copyright 2004 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177309     DOI: 10.1016/j.phrs.2004.01.004

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  53 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Authors:  Rania Abdelhedi; Nouha Abdelmoula Bouayed; Suad Alfadhli; Leila Abid; Ahmed Rebai; Najla Kharrat
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

3.  Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.

Authors:  Yipeng Ding; Dongchuan Xu; Xiyang Zhang; Hua Yang; Tingting Geng; Ping He; Jinjian Yao; Shengyang Yi; Heping Xu; Duoyi Wu; Xiang Wang; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Allele and genotype frequencies of CYP2C9 in a Korean population.

Authors:  Jung-Woo Bae; Hyun-Kyung Kim; Ji-Hong Kim; Sang-In Yang; Mi-Jeong Kim; Choon-Gon Jang; Young-Seo Park; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 5.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  CYP2D6 polymorphisms in patients with porphyrias.

Authors:  Jimena V Lavandera; Victoria E Parera; Alcira Batlle; Ana María Buzaleh
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

7.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

8.  The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients.

Authors:  Sinem Yalcıntepe; Ozturk Ozdemır; Coskun Sılan; Filiz Ozen; Ahmet Uludag; Ferhan Candan; Fatma Sılan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-03       Impact factor: 2.441

9.  Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

Authors:  K Pachkoria; M I Lucena; F Ruiz-Cabello; E Crespo; M R Cabello; R J Andrade
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

10.  Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.

Authors:  Abdoljalal Marjani; Aman Mohammad Gharanjik
Journal:  Indian J Clin Biochem       Date:  2017-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.